Cystic Fibrosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For people with cystic fibrosis:

• A confirmed diagnosis of cystic fibrosis, based on a sweat test or genetic (CFTR) mutation analysis following Cystic Fibrosis Foundation diagnostic standards
• Age 18 or older at the time of signing consent
• Pancreatic insufficiency (the pancreas does not produce enough digestive enzymes)
• A recent oral glucose tolerance test (a sugar-drink blood test) showing a specific type of blood sugar problem — either borderline, mildly abnormal, or cystic fibrosis-related diabetes without high fasting blood sugar levels
• For women: a negative urine pregnancy test at the time of enrolment

For healthy control participants (people without cystic fibrosis):

• No history of cystic fibrosis
• Age 18 or older at the time of signing consent
• A recent oral glucose tolerance test showing normal blood sugar regulation
• For women: a negative urine pregnancy test at the time of enrolment

Who may not be able to join:

For people with cystic fibrosis:

• A diagnosis of a non-cystic-fibrosis type of diabetes (such as Type 1 diabetes), or cystic fibrosis-related diabetes with high fasting blood sugar levels (fasting glucose above 126 mg/dL)
• A history of painful pancreatitis (inflammation of the pancreas) in the past year
• A previous lung or liver transplant
• Severe liver disease related to cystic fibrosis, specifically involving high blood pressure in the liver's portal vein
• A condition called dumping syndrome related to a prior stomach surgery (fundoplication)
• Other significant health conditions unrelated to cystic fibrosis, or conditions considered unstable by the investigating doctor (for example, a history of bleeding disorders or immune system problems)
• An acute illness or a change in treatment (including antibiotics) within the 6 weeks before study procedures
• Use of steroid tablets or intravenous steroids within 6 weeks before the study
• A low haemoglobin (red blood cell protein) level below 10g/dL, measured within 90 days before the first visit or at screening
• Abnormal kidney function within 90 days before the first visit or at screening, based on specific blood test results (confirm with trial site)
• Being unable to complete the specific study procedures required (confirm with trial site)
• Participants who, in the study team's opinion, may be unlikely to follow the study procedures

For healthy control participants (people without cystic fibrosis):

• Any history of clinically symptomatic pancreatitis (painful pancreas inflammation)
• Any history of liver disease
• Any illness or condition that, in the investigator's opinion, could affect the study results or create additional risk
• A low haemoglobin level below 10g/dL within 90 days before the relevant test or at screening
• Abnormal kidney function within 90 days before the relevant test or at screening, based on specific blood test results (confirm with trial site)
• Being unable to complete the specific study procedures required (confirm with trial site)
• Participants who, in the study team's opinion, may be unlikely to follow the study procedures
• Elevated levels of certain pancreatic enzymes (amylase or lipase) in the blood, above 1.5 times the upper limit of normal, within 90 days before the relevant test

Important: Always verify eligibility with the trial site directly before applying.